Vaderis Therapeutics closed an oversubscribed Series B financing of $152 million and launched HEROIC, a global phase III trial for hereditary hemorrhagic telangiectasia (HHT). The company is evaluating engasertib, an oral allosteric AKT inhibitor previously known as ALM 301. Vaderis said the financing was co-led by Life Sciences at Goldman Sachs Alternatives and TCGX, with participation from Omega Funds, EQT Life Sciences, Perceptive Advisors, Kalehua Capital, and existing investors Medicxi and Droia. The company positioned the round as capital to carry operations through potential US regulatory approval. The phase III launch is particularly notable because HHT has no approved therapies globally, and the HEROIC study is framed as a pivotal step for a disease with severe nosebleeds, anemia, and visceral arteriovenous malformations. For HHT stakeholders, the combination of a sizable late-stage fundraise and immediate phase III initiation increases the likelihood of definitive efficacy and safety evidence in the near-term pipeline.